Amplification of the EGFR gene and its truncation mutant EGFRvIII are hallmarks of glioblastoma. Although coexpression of EGFR and EGFRvIII confers a growth advantage, how EGFR and EGFRvIII influence the tumor microenvironment remains incompletely understood. Here, we show that EGFR and EGFRvIII cooperate to induce macrophage infiltration via upregulation of the chemokine CCL2. EGFRvIII was significantly enriched in glioblastoma patient samples with high CCL2, and knockout of CCL2 in tumors coexpressing EGFR and EGFRvIII led to decreased infiltration of macrophages. KRAS was a critical signaling intermediate for EGFRand EGFRvIII-induced expression of CCL2. Our results illustrate how EGFR and EGFRvIII direct the microenvironment in glioblastoma. Significance: Full-length EGFR and truncated EGFRvIII work through KRAS to upregulate the chemokine CCL2 and drive macrophage infiltration in glioblastoma. Cancer Res; 78(24); 6785-94. Ó2018 AACR.
Introduction
Glioblastoma is the most common primary brain tumor and among the most aggressive of all cancers (1) . Average survival after diagnosis is only 1 year, even in the setting of extensive chemotherapy and radiotherapy (1) . Amplification of the EGFR is identified in more than half of tumors. One third of EGFRamplified tumors also coamplify EGFRvIII, a truncation mutant of EGFR (2). Amplification of EGFRvIII always occurs in tumors that also amplify EGFR, suggesting that coamplification of those molecules confers a growth advantage (3) . Our lab previously showed that (1) EGFRvIII and EGFR cooperated to promote glioblastoma growth both in vitro and in vivo, (2) EGFRvIII was a substrate of EGFR, and (3) phosphorylation of EGFRvIII by EGFR was critical for tumorigenesis and growth (3) . EGFR and EGFRvIII cooperated to promote tumor growth more dramatically in vivo than in vitro, suggesting that tumor-extrinsic factors contribute to tumor growth (3) .
The tumor microenvironment is a critical factor in initiation and progression of glioblastoma (4, 5) . EGFRvIII potentiates the expression of IL6, IL8, and LIF, indicating that EGFRvIII signals to the glioma microenvironment through upregulating specific cytokines (6) (7) (8) . Interestingly, EGFRvIII promotes the growth of cells expressing wild-type EGFR via a paracrine IL6 and/or LIFdependent manner (8, 9) . However, how EGFR and EGFRvIII converge on cytokines to regulate immune cell infiltration remains incompletely understood.
Cytokines contribute to infiltration of immune cells including tumor-associated macrophages (TAM). Macrophages represent up to half of the glioblastoma tumor mass, with the C-C chemokine CCL2 important for macrophage infiltration (10, 11) . Levels of CCL2 are elevated in glioblastoma and drive progression by promoting immunosuppression (12, 13) . In this study, we demonstrate that EGFR and EGFRvIII cooperate through KRAS, to upregulate CCL2, promoting infiltration of macrophages.
Materials and Methods
Cell culture U87 cells expressing control vector, EGFR, EGFRvIII, and EGFR/EGFRvIII were described previously (3) . Cells were maintained in DMEM supplemented with 10% FBS and 1Â penicillinstreptomycin. A172 cells were purchased in 2017 (ATCC) and authenticated by the ATCC using short tandem repeat (STR) profiling. Cells were certified Mycoplasma-free by the ATCC. Cells were transduced with EGFR and EGFRvIII lentiviruses as described previously (3) . A172 cells expressing control vector, EGFR, EGFR-vIII, and EGFR/EGFRvIII were maintained in DMEM supplemented with 10% FBS and 1Â penicillin-streptomycin. The cells were passaged less than 15 times after thawing. GBM6 and GBM39 were from Dr. Jann Sarkaria at Mayo Clinic (Rochester, MN). The xenografted tumors were dissociated as described (14) . The cells were grown in DMEM:F12 with 20 ng/mL EGF, 20 ng/mL FGF, 1xB27 supplement, and 1Â penicillin-streptomycin. For differentiation, the cells were grown in DMEM supplemented with 10% FBS and 1Â penicillin-streptomycin. The cells were passaged less than 5 times after thawing. For cytokine-related assays, cells were grown for 24 hours in DMEM:F12 with 20 ng/mL EGF, 20 ng/mL FGF, 1xB27 supplement, and 1Â penicillin-streptomycin. MV-4-11 cells were purchased in 2015 (ATCC) and authenticated by the ATCC using STR profiling. Cells were certified Mycoplasma-free by the ATCC. These cells were cultivated in IMDM supplemented with 10% FBS at 37 C and 5% CO 2 . The cells were passaged less than 5 times after thawing. Mycoplasma status was monitored monthly in the lab using the HEK-Blue detection kit (InvivoGen).
Transwell macrophage migration assay
The assay was carried out using QCM Chemotaxis 5 mm 24-Well Cell Migration Assay Kit (Millipore) following the manufacturer's instructions. Specifically, 1 Â 10 6 macrophage cells (MV-4-11) per well were plated on transwell insert in 250 mL IMDM without FBS. Bottom chamber was filled with conditioned media (filtered through 0.45 mm filters) from equal numbers of indicated cells. After 4 hours, cells in the bottom chambers were lysed, and data were obtained by reading fluorescence 480/520nm as in the manufacturer's protocol. Results were normalized to mediumonly controls.
CRISPR knockout or siRNA knockdown of indicated genes
To generate CCL2 or KRAS CRISPR knockout, a pool of 3 different gRNA plasmids were used (Santa Cruz Biotechnology). The sequences for the CCL2 gRNAs were: 5 0 -3 0 : TACCTGGCT-GAGCGAGCCCT; 5 0 -3 0 : TTTGGGTTTGCTTGTCCAGG; 5 0 -3 0 : TCAGGATTCCATGGACCACC. The sequences for the KRAS gRNAs were: 5 0 -3 0 : TCTCGACACAGCAGGTCAAG; 5 0 -3 0 : CAAT-GAGGGACCAGTACATG; 5 0 -3 0 : TTCTCGAACTAATGTATAGA. The corresponding HDR plasmids were cotransfected following the manufacturer's instructions (Santa Cruz Biotechnology). The control siRNA and KRAS siRNA were purchased from Dharmacon.
In vivo studies
Indicated cell lines were injected into the brain of 4-to 6-weekold female BALB/C nu/nu mice. Specifically, mice were anesthetized using ketamine and xylazine. Note that 3 Â 10 5 cells were injected intracranially at 2 mm anterior and 1.5 mm lateral of the right hemisphere relative to bregma at a depth of 3 mm. Each group contains 10 mice. All mouse experiments were performed following protocols approved by UCSF's Institutional Animal Care and Use Committee.
IHC staining
Excised tumors from mice were fixed with 10% neutral-buffered formalin for 24 hours and changed to 70% ethanol. Tumors were paraffin-embedded and sectioned by the Brain Tumor Research Center at UCSF. For IHC, slides were deparaffinized, and antigen retrieval was performed using a pressure cooker. The Mouse on Mouse (M.O.M.) basic kit (Vector laboratories) was used for masking endogenous mouse antigen. The VECTASTAIN ABC reagent (Vector laboratories) was used for signal detection. The CD45 antibody (05-1410) was purchased from EMD Millipore and was used at a concentration of 1:50. The CD38 (ab216343), CD68 (ab955), and TMEM119 (ab209064) antibodies were purchased from Abcam and were used at a concentration of 1:100. The CD206 antibody (AF2535SP) was purchased from R&D Systems and was used at a concentration of 1:50. Images were taken using a Zeiss AxioImager M1 microscope. Cells were quantified using Image J.
Immunofluorescent staining
Formalin-fixed paraffin sections from primary grade IV human glioblastoma tumor tissues were deparaffinized in xylene and rehydrated over a graded ethanol series, followed by treatment in 10 mmol/L citrate buffer at pH 6.0 for 20 minutes in a steamer for antigen retrieval. Tissue sections were equilibrated in TBST and then blocked for 10 minutes with Ultravision Protein Block (Thermo Scientific) and incubated overnight at 4 C with primary antibodies against EGFR (mouse monoclonal DAK-H1-WT, Dako, 1:50), EGFRvIII (rabbit polyclonal 6549, Celldex, 1:100), and CD45 (rat monoclonal SM1744P, Acris, 1:100), diluted in Dako REAL Antibody Diluent. Three washing steps in TBST were followed by incubation with secondary antibodies at room temperature for 1 hour diluted in Dako REAL Antibody Diluent (anti-mouse AF488, anti-rabbit AF594, anti-rat AF647, Thermo Fisher, 1:1,000). Three washing steps in TBST were followed by incubation of the slides with DAPI diluted in PBS to a final concentration of 1 mg/mL for 5 minutes at room temperature. Following repeated washing, stained sections were mounted in ProLong Gold antifade reagent (Thermo Fisher) and sealed using nail polish. Fluorescent images were taken using a Leica TCS SP8 Sted microscope with either a 100x oil immersion objective or a 40x water immersion objective. Taken images were further processed using the Leica Las X software, Adobe Photoshop, and Adobe InDesign.
Real-time PCR
RNA was extracted using the Quick-RNA MiniPrep Kit according to the manufacturer's instructions (ZYMO Research). cDNA was produced using the iScript cDNA synthesis Kit (Biorad). Realtime PCR was performed using SYBR FAST ABI Prism qPCR kit (KAPA Biosystems) on an AB7900HT real-time PCR machine (Applied Biosystems). The primers for CCL2 were as follows:
Western blotting
Cells were lysed using RIPA buffer with cOmplete Mini protease inhibitor cocktail (Roche) and PhosSTOP (Roche). The IkB (9242) and p-IkB (9246) antibodies were purchased from Cell Signaling Technology and used at a concentration of 1:500. The Actin antibody (sc-1615) was purchased from Santa Cruz Biotechnology and used at a concentration of 1:1,000. The KRAS antibody (SAB2101297) was purchased from Sigma and used at a concentration of 1:500.
Cell surface EGFR/EGFRvIII staining and FACS sorting
Cells were dissociated using Accutase (Innovative Cell Technologies), washed with cell staining buffer with sodium azide (BioLegend), and stained with an Alexa Fluor 488 anti-human EGFR antibody (AY13, BioLegend) for 20 minutes. Cells were sorted using a FACSAria3 sorter (BD) at the UCSF Laboratory for Cell Analysis core facility. Approximately 20,000 cells were sorted for each population.
Cytokine array
Cytokine levels in conditioned medium from equal number of indicated cell lines were measured using Human Cytokine Array Panel A (R&D Systems #ARY005) following the manufacturer's instructions.
RNA sequencing
RNA was extracted using Quick-RNA MiniPrep kit according to the manufacturer's instructions (ZYMO Research). RNA sequencing (RNA-seq) was performed with Illumina HiSeq4000 at University of California, Berkeley. Results were analyzed using Galaxy (https://usegalaxy.org/). The raw data were deposited to GEO (accession number: GSE117838). Heat map was generated using GENE-E. KEGG pathway analysis was performed using CPDB (http://cpdb.molgen.mpg.de/). Gene set enrichment was performed using GSEA oncogenic signatures (http://software. broadinstitute.org/gsea/index.jsp).
The Cancer Genome Atlas data analysis
EGFRvIII data were obtained from ref.
2. CCL2 expression levels were downloaded from http://gliovis.bioinfo.cnio.es/ [The Cancer Genome Atlas (TCGA), platform HG-133A]. Three cases with unknown EGFR status and one case with EGFRvIII and EGFR euploid were excluded from analysis.
Statistical analysis
Unless otherwise noted, one-way ANOVA was performed, and P < 0.05 was considered statistically significant.
Results

EGFRvIII cooperates with EGFR to induce infiltration of CD45 þ cells
To further clarify how EGFR and EGFRvIII promote tumor growth, we tested whether EGFR and EGFRvIII influenced infiltration of immune cells. We analyzed EGFRvIII-positive sections from primary human glioblastoma, for expression of EGFR, EGFRvIII, and CD45, a pan hematopoietic lineage marker ( Fig. 1A) . Cells double-positive for EGFR and EGFRvIII were surrounded by CD45-positive cells (Fig. 1A ). Glioblastoma tumors are heavily infiltrated by immune cells, with infiltrating macrophages representing up to half of the tumor mass (11) . To test whether inhibition of EGFR and EGFRvIII decreased macrophage attraction, we analyzed short-term cultures from two primary patient-derived xenograft lines (GBM6 and GBM39-both EGFR and EGFRvIII coamplified; ref. 15 ), treated with DMSO or the EGFR inhibitor lapatinib. Conditioned media from equal numbers of DMSO-treated GBM6 and GBM39 cells attracted more CD45 þ macrophages than media from lapatinib-treated GBM6 cells ( Fig. 1B and C) .
To test the function of EGFR and EGFRvIII in attracting macrophages in an isogenic system, we used our published cell lines, which stably express EGFR and EGFRvIII singly or together in U87: MG cells (3). Conditioned media from cells coexpressing EGFR and EGFRvIII attracted significantly more CD45 þ macrophages than conditioned media from cells expressing EGFR or EGFRvIII alone (Fig. 1D ). Intracranial xenografted tumors coexpressing EGFR and EGFRvIII also showed significantly more CD45 þ cells, compared with tumors expressing either EGFR or EGFRvIII alone ( Fig. 1E and F) . Together, these results show that coexpression of EGFR and EGFRvIII increases infiltration of immune cells in glioblastoma tumors.
Infiltration of both M1 and M2 macrophages in response to EGFR and EGFRvIII
TAMs can polarize towards M1 proinflammatory and antiinflammatory M2 phenotypes, respectively (16) . However, M1 and M2 macrophages may coexist (17) , depending on the balance of activating and inhibitory signals and their interplay with the tumor microenvironment (17) . We stained intracranial xenografted tumors with M1 macrophage marker CD38 and M2 macrophage marker CD206. Tumors coexpressing EGFR and EGFRvIII showed significantly more CD38 þ cells and CD206 þ cells, compared with tumors expressing either EGFR or EGFRvIII singly ( Fig. 2A-C) . Thus, in these xenografted tumors, coexpression of EGFR and EGFRvIII increases infiltration of both M1 and M2 macrophages.
EGFRvIII cooperates with EGFR to induce infiltration of macrophages and microglia
To separately assess recruitment of macrophages from recruitment of brain-resident microglia, we injected tumor cells into flank regions of nude mice, a region free of microglia. Established tumors coexpressing EGFR and EGFRvIII showed significantly more infiltration of CD68 þ monocyte lineage cells, compared with tumors expressing either EGFR or EGFRvIII alone (Fig. 2D) . Microglia, a brain-resident macrophage population, constitutes 5% to 10% of total brain cells (18) . We therefore also analyzed intracranial xenografts, staining with TMEM119, a marker of microglia (19) . Tumors coexpressing EGFR and EGFRvIII also showed significantly more TMEM119 þ cells, compared with tumors expressing either EGFR or EGFRvIII alone ( Fig. 2E) . Quantification further validated the results (Fig. 2F and G) . Together, these results suggest that EGFR and EGFRvIII cooperate to attract both peripheral macrophages and microglia into tumors.
Induction of cytokines and chemokines in response to EGFRvIII and EGFR
Next, we performed RNA-seq to determine whether coexpression of EGFR and EGFRvIII influenced the abundance of cytokines, to promote infiltration of CD45 þ cells. Glioblastoma cells coexpressing EGFR and EGFRvIII upregulated the transcription of a large group of cytokines and chemokines, compared with cells expressing vector, EGFR, or EGFRvIII alone. Top hits included IL6 and IL8, previously reported as regulated by EGFRvIII (20) , and new candidates including IL1RN, IL33, IL11, and CCL2 (Fig. 3A) . Pathway enrichment analysis demonstrated that genes in cytokine-cytokine receptor interaction and chemokine signaling pathways were upregulated cooperatively by EGFR and EGFRvIII (Fig. 3B) . Using real-time PCR, we verified that EGFR and EGFRvIII upregulated transcription of IL1B, CCL2, LIF, CXCR4, and CXCL12 ( Fig. 3C and D; Supplementary Fig. S1A ).
We verified these results in a second-line, A172 glioblastoma cells, demonstrating that coexpression of EGFR and EGFRvIII also led to increased transcription of CCL2 and IL1B ( Supplementary  Fig. S1B ). Next, we ruled out the possibility that increased receptor density on the surface of cells coexpressing EGFR and EGFRvIII accounted for induction of CCL2. We demonstrated that cells expressing EGFR or EGFRvIII alone, at cell surface receptor density comparable with that of cells coexpressing EGFR and EGFRvIII, failed to induce significant amounts of CCL2. We labeled cells with Alexa Fluor 488-conjugated EGFR antibody (recognizes both EGFR and EGFRvIII), and sorted cells with comparable EGFR/EGFRvIII levels ( Supplementary Fig. S1C ). For each cell line, an EGFR/EGFRvIII-high and an EGFR/EGFRvIII-low population were sorted ($10-fold difference in signal intensity). Within each sorted population, CCL2 mRNA expression was analyzed by real-time PCR ( Supplementary Fig. S1C and S1D). Cells expressing EGFR or EGFRvIII alone, at comparable cell surface receptor level as cells coexpressing EGFR and EGFRvIII, expressed significantly less CCL2 ( Supplementary Fig. S1D ). Cells with a lower cell surface EGFR/EGFRvIII density expressed significantly less CCL2 than those cells with a higher cell surface EGFR/ EGFRvIII density ( Supplementary Fig. S1D ). These results indicated that EGFR and EGFRvIII cooperate to induce CCL2 expression, and that receptor density affected the induction level.
We went onto analyze expression of proteins using cytokine arrays. Consistent with the RNA-seq data, coexpression of EGFR and EGFRvIII also upregulated IL1B, CCL2, and other cytokine at the protein level ( Fig. 3E-G; Supplementary Fig. S2 ). In addition, we treated short-term cultures of GBM6 and GBM39 (EGFR/ EGFRvIII coamplified) with lapatinib. This treatment led to significantly less production of CCL2 compared with control cells (Fig. 3H and I) . Collectively, these data suggest that EGFR and EGFRvIII cooperate to drive expression of cytokines and chemokines.
EGFR and EGFRvIII signal through CCL2 to recruit macrophages CCL2, among the most prominent chemokines for macrophage attraction, was induced by EGFR and EGFRvIII (Fig. 3) . Incubation of conditioned media from cells coexpressing EGFR and EGFRvIII, with a CCL2-neutralizing antibody, significantly reduced macrophage attraction (Fig. 4A ). Conditioned media from cells coexpressing EGFR and EGFRvIII, after CRISPR/Cas9-mediated deletion of CCL2, also led to decreased macrophage infiltration ( Fig. 4B; Supplementary Fig. S3A ). Knockout of CCL2 in intracranial xenografted tumors coexpressing EGFR and EGFRvIII led to significant decreases in the abundance of infiltrating CD45 þ cells ( Fig. 1E and F) and modestly enhanced survival (Fig. 4C ). When we sacrificed animals at end point, tumors were localized to forebrains, where we injected the tumor cells. To extend this result, we analyzed genomic data from human glioblastoma. In TCGA datasets, EGFRvIII amplification was enriched significantly in samples with high expression of CCL2 mRNA (Fig. 4D ). 
EGFR and EGFRvIII signal through KRAS to upregulate expression of cytokines
To determine how EGFR and EGFRvIII activate cytokines and chemokines, we looked for oncogenic signatures in gene sets enriched by EGFR and EGFRvIII (GSEA analysis). The top five gene sets were all related to KRAS (Fig. 5A ). Knockout of KRAS in cells coexpressing EGFR and EGFRvIII decreased expression of cytokines and chemokines including CCL2 ( Fig. 5B and C; Supplementary Fig. S3B ). Consistently, conditioned media from cells coexpressing EGFR and EGFRvIII, and knocked out for KRAS, attracted fewer macrophages than conditioned media from the same cells with intact KRAS (Fig. 5D ). Conditioned media from cells transfected with KRAS siRNA attracted significantly fewer macrophages compared with conditioned media from cells transfected with control siRNA ( Supplementary Fig. S3C and S3D) . In response to treatment with CCL2-neutralizing antibody, conditioned media from KRAS siRNA-transfected cells attracted fewer macrophages compared with conditioned media from control siRNA-transfected cells ( Supplementary Fig. S3D ). These results indicate that although CCL2 is a major chemokine for EGFR/EGFRvIII/KRAS-induced macrophage attraction, other KRAS-dependent cytokines also play minor roles. Intracranial tumors coexpressing EGFR and EGFRvIII and knocked out for KRAS also showed decreased infiltration by CD45 þ cells ( Fig.  1E and F) . These data indicate that EGFR and EGFRvIII signal through KRAS to upregulate expression of CCL2, and to promote infiltration by TAMs.
The NF-kB pathway is an important pathway regulating inflammation. We tested IkB phosphorylation, a commonly used readout for NF-kB activation. Under the same condition as our RNA-seq and cytokine array, we failed to observe increased phosphorylation of IkB ( Supplementary Fig. S4 ). This result suggests that other pathways might be important in regulating EGFR/EGFRvIII/KRAS-induced cytokine expression.
Our RNA-seq results show that coexpression of EGFR and EGFRvIII upregulated CCL2, as well as stem cell markers such as CD90/THY1 and SOX1 ( Supplementary Fig. S5A ; refs. 21, 22) . Expression of these stem cell markers was dependent on KRAS ( Supplementary Fig. S5A ). We also cultured GBM6 and GBM39 in stem cell medium or differentiated them with DMEM and FBS. Consistently, GBM6 and GBM39 expressed less CCL2, CD90/THY1, and SOX1 in differentiated media comparing with stem cell media ( Supplementary Fig. S5B ). These observations suggest that EGFR and EGFRvIII drive expression of CCL2 preferentially in glioblastoma stem cells.
Discussion
Amplification of EGFR and EGFRvIII represents hallmark genetic changes in glioblastoma. Amplification of EGFRvIII occurs only in tumors that amplify EGFR, suggesting that those two molecules could cooperate to promote tumor growth. Based on this coamplification, we and others have previously studied EGFR and EGFRvIII in human cancers, to assess cooperation (3, 8, 9, 23, 24) . We previously demonstrated coexpression of EGFR and EGFRvIII proteins in rare individual cells within glioblastoma, in all 11 of 11 primary human glioblastoma samples analyzed (3). To address whether this coexpression was coupled to cooperation between EGFR and EGFRvIII, we went on to show that EGFR and EGFRvIII cooperated in transformation in vitro and in vivo, that EGFR phosphorylated EGFRvIII, and that these two kinases converged on STAT3 (3). These published data illustrate clearly that EGFR and EGFRvIII cooperated through a cell-intrinsic mechanism. In this article, we demonstrate that this cooperation extends to cell-extrinsic signaling. We show that EGFR and EGFRvIII promote cytokine expression in vitro, leading to in vivo macrophage attraction through the KRAS pathway. These observations provide new insights that cooperation of those two molecules can modulate the tumor microenvironment.
Glioblastoma tumors are heavily infiltrated by immune cells including macrophages, myeloid-derived suppressor cells, and regulatory T cells (25) , among which, infiltrating macrophages can represent half of the tumor mass (11) . Here, we provide evidence that EGFR and EGFRvIII cooperatively upregulate CCL2 and promote infiltration of macrophages. Although CCL2 is a major chemokine recruiting macrophages, knockout of CCL2 in cells coexpressing EGFR and EGFRvIII did not completely block EGFR-and EGFRvIII-induced macrophage attraction in vitro, indicating that other chemokines also contribute to macrophage recruitment. Our RNA-seq results suggest CCL8 as an additional candidate macrophage-recruiting chemokine (26) , as CCL8 was also upregulated in cells coexpressing EGFR and EGFRvIII.
Within a glioblastoma tumor, the majority of cells express predominantly EGFR or EGFRvIII, with only rare cells coexpressing both EGFR and EGFRvIII (3). These observations suggest that EGFR and EGFRvIII may signal in glioma stem cells, with subsequent mitoses leading them to segregate independently to more differentiated daughter cells. Our results are consistent with observations that unlike their differentiated progeny, glioma stem cells show an increased capacity for active chemoattraction and recruitment of macrophages, through upregulation of cytokines (4). Our results suggest a possible link between KRAS-mediated cytokine expression and glioblastoma stemness.
Macrophages can be divided into tumor-suppressive and tumor-promoting classes (27) . CCL2 can polarize macrophages toward a tumor-promoting, immunosuppressive phenotype (28) . Our results showed that coexpression of EGFR and EGFRvIII promoted infiltration of both tumor-promoting (M2) and tumorsuppressive macrophages (M1). This may be one reason why knockout of CCL2 in cells coexpressing EGFR and EGFRvIII only modestly affected survival. Another issue is that macrophages induced by EGFR and EGFRvIII cannot in-turn influence the abundance or cellular activity of lymphocytes, which are absent in the nude mouse models used in this study. Notably, it was reported that B cells and T cells in the immune system, which nude mice lack, drove macrophage polarization to M2 (29, 30) . Our human cell-based model systems pose real limitations (31) . Although immunocompetent mouse models are better than nude mice for studying the tumor microenvironment, we are unaware of immunocompetent models for glioblastoma in which EGFR and EGFRvIII are clear drivers. Such a model, which we are actively trying to develop, is essential to further delineate functionally how EGFR and EGFRvIII modulate the microenvironment in glioblastoma.
